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Abstract To investigate the effects soy isoﬂavones in
established cancers, the role of genistein, daidzein, and
combined soy isoﬂavones was studied on progression of
subcutaneous tumors in nude mice created from green
ﬂuorescent protein (GFP) tagged-MDA-MB-435 cells.
Following tumor establishment, mice were gavaged with
vehicle or genistein or daidzein at 10 mg/kg body weight
(BW) or a combination of genistein (10 mg/kg BW),
daidzein (9 mg/kg BW), and glycitein (1 mg/kg BW) three
times per week. Tumor progression was quantiﬁed by
whole body ﬂuorescence image analysis followed by
microscopic image analysis of excised organs for metas-
tases. Results show that daidzein increased while genistein
decreased mammary tumor growth by 38 and 33%
respectively, compared to vehicle. Daidzein increased lung
and heart metastases while genistein decreased bone and
liver metastases. Combined soy isoﬂavones did not affect
primary tumor growth but increased metastasis to all
organs tested, which include lung, liver, heart, kidney, and
bones. Phosphoinositide-3-kinase (PI3-K) pathway real
time PCR array analysis and western blotting of excised
tumors demonstrate that genistein signiﬁcantly downregulated
10/84 genes, including the Rho GTPases RHOA, RAC1,
and CDC42 and their effector PAK1. Daidzein signiﬁcantly
upregulated 9/84 genes that regulate proliferation and
protein synthesis including EIF4G1, eIF4E, and survivin
protein levels. Combined soy treatment signiﬁcantly
increased gene and protein levels of EIF4E and decreased
TIRAP gene expression. Differential regulation of Rho
GTPases, initiation factors, and survivin may account for
the disparate responses of breast cancers to genistein and
daidzein diets. This study indicates that consumption of soy
foods may increase metastasis.
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Introduction
Breast cancer is the most commonly diagnosed form of
cancer in women 40–55 years of age and is a major cause
of cancer deaths [1]. Metastatic breast cancer, where the
cancer cells spread using motile mechanisms and establish
tumors at distant vital sites, is much harder to eradicate and
is often the cause of death from breast cancer. Interest in
soy isoﬂavones has been fueled by studies that demonstrate
a lower incidence of menopausal symptoms, osteoporosis,
cardiovascular disease, breast and endometrial cancers in
Asian women who have a diet rich in soy products [2, 3].
The anti-breast cancer effects of soy foods have been
shown to be effective at early stages of carcinogenesis and
most studies have focused on prevention of breast cancer
risk by soy isoﬂavones [4, 5]. Moreover, their beneﬁts as
chemopreventives for breast cancer or as substitutes for
hormone replacement therapies (HRT) remain controver-
sial [2, 6, 7]. The effect of soy foods on established cancers
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soy consumption for women at high risk for breast cancer
or survivors of breast cancer are not known [2]. The present
study was designed to understand the impact of soy foods
on established breast cancer.
Soy isoﬂavones are present in soy foods as aglycones
where genistein, daidzein, and glycitein make up 50%,
40%, and 10%, respectively, of the total soybean isoﬂav-
ones [8]. Isoﬂavones are structurally similar to estrogen and
genistein and daidzein, but not glycitein, can bind to and
transactivate estrogen receptors (ER) with a higher afﬁnity
for ERb [9, 10]. The chemopreventive cytotoxic effects of
genistein have been shown for both ER (?) and ER (-)
breast cancer cell lines including the MDA-MB-435 cells
used in this study [11–13]. In vivo, genistein has also been
shown to inhibit cancer initiation of chemically-induced
rodent models [14, 15]. A study that used a lung metastatic
variant of MDA-MB-435 reported that genistein (750 lg/g
mouse chow) administered prior to mammary tumor cell
inoculation or following surgical removal of the primary
mammary tumor resulted in reduced lung metastases [16].
Moreover, recent data indicate that genistein inhibits inva-
sion, metastasis, and angiogenesis in vitro and in vivo in a
number of cancers including breast cancer [16–19]. How-
ever, other studies have shown that soy isoﬂavones, par-
ticularly genistein, increase the growth of MCF-7 human
breast cancer cells and tumors in ovariectomized nude mice
and metastatic progression of prostate cancer [20, 21].
These contradictory results may be due to the fact that the
hormonal milieu can be an important factor in determining
the in vivo effects of isoﬂavones, where reports indicate that
genistein and daidzein can block physiological estrogen-
induced rat pituitary tumor cell growth [22].
At the molecular level, soy isoﬂavones have estrogenic/
antiestrogenic, antioxidant and anti-angiogenic activities
and may affect cancer due to their effects on apoptosis, cell
cycle progression, growth, and differentiation. In addition
to attenuating cell growth via inhibition of ER, genistein
has also been shown to block growth factor- and cytokine-
stimulated proliferation of cells. Genistein affects cellular
function via inhibition of enzymes required to convert
androgens to E2 (17 beta-steroid oxidoreductase and aro-
matases), tyrosine protein kinases, cytochrome p450
enzymes, and cycloxygenase 2 [6, 23, 24]. Genistein also
modulates the activity of topoisomerase II, enzymes
involved in phosphoinositide (PI) turnover, transforming
growth factor (TGF)-b signaling cascades, ER levels,
growth factors and their receptor levels, mitogen activated
protein kinases (MAPK) and p38 MAPK activity, uroki-
nase-type plasminogen activator (uPA) and matrix
metalloproteinases (MMP) secretion, NF-jB, focal adhe-
sion kinase (FAK), Akt and WNT signaling pathways, and
DNA methylation [17, 19, 24–33].
The speciﬁc effects of daidzein or glycitein on signaling
pathways have not been investigated as comprehensively
as with genistein. At high concentrations, daidzein exerts
anti proliferative effects by the generation of reactive
oxygen species (ROS), disruption of mitochondrial trans-
membrane potential; downregulation of Bcl-2, growth
factors, cytokines, cyclin dependent kinases, and DNA
checkpoint proteins; and upregulation of Bax and cyclin
dependent kinase inhibitors [25, 34]. One study using
10 lM glycitein has shown inhibitory effects on cell
growth and induction of apoptosis by reduced Bcl-2/Bax
ratio in MCF-7 breast cancer cells [10]. Interestingly, most
of the studies detailing the effects of individual soy iso-
ﬂavones focus on their effects on non-metastatic cell lines
and the effect of soy isoﬂavones at multiple stages of the
metastatic cascade remain to be elucidated [35]. The
present study was conducted to test the effects of soy
isoﬂavones using the MDA-MB-435 cell line as a model
for a highly invasive and metastatic cancer. Future studies
will involve a more comprehensive investigation of the
signaling pathways regulated by genistein, daidzein, and
glycitein.
The origin of the MDA-MB-435 cell line has been
questioned by comparative genomic hybridization studies
that report MDA-MB-435 and M14 melanoma to be
identical cell lines [36]. However, as reviewed in [37], both
cell lines may be of MDA-MB-435 breast cancer origin
rather than of melanoma origin due to the following
rationale. The MDA-MB-435 cell line was isolated from a
pleural effusion of a female patient with breast cancer and
still has two X chromosomes; expresses milk proteins and
lipids; and when transfected with the nm23 metastasis
suppressor gene, MDA-MB-435 cells show the morpho-
logic features of normal breast epithelial cells, including
acinus formation in three-dimensional culture [38]. More-
over, MDA-MB-435 cells have been extensively used to
investigate metastasis from the mammary fat pad and
remains as one of few models available for experimental
metastasis in nude mice [39, 40]. As with most metastatic
breast cancers, this cell line is ER (-), and genistein is
known to inhibit growth and induce apoptosis of MDA-
MB-435 cells [13].
In the present study, we used a green ﬂuorescent protein
(GFP)-tagged bone metastatic variant of the MDA-MB-435
cell line (described in [39]) to investigate the effect of
dietary isoﬂavones (genistein and daidzein) individually
and in the combination found in soy foods (genistein 50%,
daidzein 40%, and glycitein 10%) on established breast
cancer growth and metastasis. Herein, we report differen-
tial effects where genistein decreased while daidzein
increased primary tumor growth, metastasis, and expres-
sion of genes and proteins involved with tumor progres-
sion. Combined soy isoﬂavones did not affect primary
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123tumor growth but increased metastasis. Therefore, the
results of this study indicate that consumption of soy
products may have differential and complex effects on




A bone metastatic variant of GFP-MDA-MB-435 cell line
was used (gift of Dr. Danny Welch, The University of
Alabama at Birmingham) and cultured as described in [39].
The development of this cell line and its usefulness as a
model for experimental metastasis is described in [41].
Animals
Female athymic nu/nu mice, 5 week old (Charles River
Laboratories, Wilmington, MA) were maintained and cared
for as in [42, 43]. The mice received autoclaved AIN 76-A
phytoestrogen-free diet (Tek Global, Harlan Teklad,
Madison, WI) and water ad libitum. This protocol was
approved by the Universidad Central del Caribe IACUC.
Tumor model
GFP-MDA-MB-435 cells (*1 9 10
6) in Matrigel (BD
Biosciences, San Jose, CA) were injected into the mam-
mary fat pad under isoﬂuorane inhalation as described in
[43, 44]. After tumor establishment (1 week post-inocula-
tion), the animals were randomly divided into control and
experimental groups.
Diet administration
Study 1. Nude mice (n = 10/group) were orally gavaged
with vehicle (90% corn oil, 10% ethanol), 10 mg/kg BW
genistein, or 10 mg/kg BW daidzein in a 100 ll volume
three times per week. Study 2. Nude mice (n = 10/group)
were orally gavaged with vehicle or soy isoﬂavones
(10 mg/kg-BW genistein, 9 mg/kg-BW daidzein, and
1 mg/kg-BW glycitein) in a 100 ll volume three times per
week. Treatments continued until sacriﬁce at d 78.
For all treatments, some early deaths occurred due to
metastatic burden. Therefore, only 8 mice/group remained
for the ﬁnal analysis.
Whole body ﬂuorescence image analysis
The mice were imaged following tumor establishment, and
twice per week thereafter, until d 77 (one d prior to
sacriﬁce at d 78). Tumor progression was monitored by
ﬂuorescence image analysis and quantiﬁed as in [42].
Relative tumor area was calculated as the ﬂuorescence
intensity of each tumor on day of imaging relative to the
ﬂuorescence intensity of the same tumor on d 01 of diet
administration using ImageJ software (National Institutes
of Health, Bethesda, MD).
Analysis of metastases
Following sacriﬁce, lungs, kidneys, liver, femurs, and
hearts were excised and immediately stored in liquid
nitrogen. Stored organs were thawed and analyzed using an
Olympus MVX10 ﬂuorescence stereoscope and an Olym-
pus DP71 microscope digital camera (Olympus America,
Inc, Melville, NY) as in [43].
Statistical analysis
Statistical analyses were done using Microsoft excel. P
values were determined using Students t test and values
B 0.05 were considered signiﬁcant.
Real time RT-PCR analysis
Solid primary tumors (n = 3/treatment group) were
excised, cut in half, and immediately stored in ‘‘RNAlater’’
(Ambion, Austin, TX) for analysis as described in [43].
Total RNA extraction and gDNA elimination was per-
formed using the Qiagen RNeasy Kit (Qiagen, Valencia,
CA). RNA (0.5 lg) was used to synthesize cDNA using C-
03 RT
2 First Strand Kit (SA Biosciences, Frederick, MD),
and gene expression proﬁles were investigated using the
human PI3-K/Akt signaling Pathway (PAHS-058A) RT
2
Proﬁler
TM PCR arrays (SA Biosciences, Frederick, MD).
The spreadsheets, gene tables, and template formulas
included with the PCR array package were used to calculate
relative changes in gene expression as described in [43].
Western blot analysis
Flash frozen primary tumors were lysed using a homo-
genizer (Brinkmann Polytron, Mississauga, ONT, Canada)
in lysis buffer (10% SDS, 10% sodium deoxycholate, 1%
Triton-X 100, 1% Igepal, and protease and phosphatase
inhibitors) and quantiﬁed using the Precision Red protein
assay kit (Cytoskeleton, Inc. Denver, CO). Equal total
protein amounts were resolved on SDS-PAGE gels and
Western blotted using anti-RhoA, anti-Rac1, anti-Cdc42,
and anti-PAK1 (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA), anti-GFP (Abcam, Cambridge, MA), anti-
actin (Sigma–Aldrich Comp., St. Louis, MO), anti-eIF4G
and anti-eIF4E (Epitomics, Inc., Burlingame, CA), and
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123anti-survivin (Cell Signaling Technology, Inc., Danvers,
MA) antibodies. The integrated density of positive bands
was quantiﬁed using ImageJ software. Quantiﬁcation of
tumor proteins was ensured by normalizing the integrated
densities of positive bands for all antibodies to the inte-
grated density of the same tumor lysate western blotted for
GFP or actin.
Results
Effect of soy isoﬂavones on primary mammary tumor
growth
Study 1: effects of major soy isoﬂavones, genistein
and daidzein, on primary mammary tumor growth
To test the effect of genistein and daidzein on metastatic
breast cancer progression in vivo, we established mammary
fat pad tumors from GFP-MDA-MB-435 cancer cells as in
[44]. One week following cell inoculation, mice were gavaged
with vehicle, 10 mg/kg BW genistein, or 10 mg/kg BW
daidzein thrice/week. These diets were selected to repre-
sent high levels of soy consumption, that were correlated
with reduced breast cancer risk [45] and as per similar
studies in rodents that demonstrated reduced tumor pro-
gression with genistein [46, 47]. Tumor growth remained
linear during the course of the study. After 40 days, geni-
stein-treated mice demonstrated reduced tumor growth
while daidzein-treated mice demonstrated accelerated
tumor growth compared to vehicle (Fig. 1a). Similar to a
study that showed a trend in reduced MDA-MB-435
mammary tumor volume in response to dietary genistein
[16], we report decreased tumor growth from mice on the
genistein diet compared to vehicle controls. Both ﬂuores-
cence images and weights show that daidzein signiﬁcantly
increased (P\0.05) mammary tumor growth by 38% and
genistein inhibited (P\0.05) mammary tumor growth by
33% compared to controls (Fig. 1b, c).
Study 2: effects of combined soy isoﬂavones on primary
mammary tumor growth
Since individual treatments of genistein or daidzein pro-
duced clearly disparate effects on mammary tumor growth,
we performed a second study to investigate the effects of a
combined diet of genistein, daidzein, and glycitein, the
major soy isoﬂavones in the ratio commonly found in fer-
mented soy foods. Treatment with combined soy isoﬂav-
ones resulted in a similar response as vehicle treatment in
primary tumor growth (Fig. 1a). This data on the effect of
combined soy isoﬂavones on ER (-) mammary tumor
growth is similar to a previous study with ER (?) mammary
tumor models that reported no effect of soy isoﬂavone
extract on mammary tumor growth in nude mice [48].
Effect of soy isoﬂavones on metastasis
Study 1: effects of major soy isoﬂavones, genistein
and daidzein, on metastasis
To investigate the effect of soy isoﬂavones on metastasis of
established carcinomas, the metastatic foci in lung, bone,
Fig. 1 Effect of soy isoﬂavones on the growth of MDA-MB-435
mammary fat pad tumors. One week following injection of
MDA-MB-435 cells, mice (10/treatment) were fed vehicle (Veh),
10 mg/kg-BW genistein (Gen), or daidzein (Daid), or soy isoﬂavones
(10 mg/kg-BW genistein, 9 mg/kg-BW daidzein, and 1 mg/kg-BW
glycitein) 39 a week. Whole body ﬂuorescence images were acquired
29 a week. a Average relative tumor area with days post injection,
calculated as the area of ﬂuorescence on each day of imaging as a
function of the ﬂuorescence intensity of the same tumor on d 01.
b Representative digital images of GFP-MDA-MB-435 tumors
following vehicle, genistein, or daidzein diets at d 77. c Average
mammary tumor growth as quantiﬁed from digital images acquired on
d 77, made relative to same tumor image on d 01. Values are
mean ± SEM (n = 8). Asterisk denotes statistical signiﬁcance at
P\0.05 compared to vehicle control
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123liver, heart, and kidney were analyzed. Whole body image
analysis of mice at the time of sacriﬁce demonstrated that
37.5% of vehicle or daidzein-fed mice demonstrated easily
detectable lymph node metastases while only 25% of
genistein fed mice demonstrated lymph node metastases,
although these ﬁndings were not statistically signiﬁcant
when compared to the vehicle treated mice (data not
shown). Metastatic lesions in other excised organs were
imaged using a ﬂuorescence stereoscope. As shown in the
examples of lung images in Figs. 2a and 3a, ﬂuorescent
images were digitally acquired and used for quantiﬁcation
of metastatic efﬁciency. Unlike studies that report only the
number of mice with metastases at an organ site by random
histopathology analysis, our comprehensive ﬂuorescence
image analysis allowed the quantiﬁcation of the total
number of metastatic foci per organ as well as area and
integrated density of metastatic foci.
Even though the number of mice with lung metastases
following genistein were slightly reduced compared to
vehicle controls (Fig. 2e), as has been reported before by
Fig. 2 Effect of genistein and
daidzein on metastasis.
a Images of representative lungs
and ﬂuorescence image analysis
of lungs from mice following
vehicle genistein, or daidzein
treatment. The average area of
ﬂuorescent metastatic foci was
calculated from excised lungs
after vehicle, genistein, or
daidzein treatment.
b Fluorescence image analysis
of hearts from mice following
vehicle, genistein, or daidzein.
c Fluorescence image analysis
of bones from mice following
vehicle genistein, or daidzein.
d Fluorescence image analysis
of livers from mice following
vehicle genistein, or daidzein.
Average area or integrated
density of ﬂuorescent metastatic
foci/mouse ± SEM for n = 8/
treatment is shown. Asterisk
denotes statistical signiﬁcance
(P\0.05) compared to vehicle
controls. e The percentage of
mice with metastases for each
organ (bone, heart, kidney,
liver, lung) after vehicle,
genistein, or daidzein treatment,
as detected from ﬂuorescence
images (n = 8)
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123histopathology of lung metastases [16], the total area of
ﬂuorescent lesions in the lungs from genistein-treated mice
was not statistically signiﬁcant from controls. Lungs from
daidzein-treated mice presented with increased number and
area of metastatic lesions with an average of 74 metastatic
foci/lung compared to 35 metastatic foci/lung from vehi-
cle-treated mice. The lung metastases from daidzein treated
mice were larger than the foci from vehicle treated mice
with a statistically signiﬁcant 12-fold increase in area of
ﬂuorescence (P\0.05, Fig. 2a).
Similarly, daidzein treatment exhibited more heart
metastases than vehicle or genistein treatments. Heart
metastases were observed from 50% of vehicle, 37.5% of
genistein, and 87.5% of daidzein treated mice (Fig. 2e).
Vehicle or genistein treated mice demonstrated an average
of 2 metastatic foci/heart while daidzein resulted in an
average of 4.75 metastatic foci/heart. Daidzein treatment
demonstrated a 14-fold signiﬁcant increase in both area and
integrated density of heart metastases compared to vehicle
(P\0.03, Fig. 2b).
Inthekidneys,37.5%ofvehicleorgenistein-treatedmice
and 87%of daidzein-treated mice presented with metastases
(Fig. 2e). Vehicle treatment resulted in an average area of
kidneymetastasis/mouseof11.6 ± 7.1 mm
2whilethemice
from the genistein treatment demonstrated an average area
of 4.9 ± 1.7 mm
2 and daidzein treatment resulted in an
average area of 18.9 ± 9.7 mm
2. However, both the chan-
ges in area or integrated density of metastatic foci in the
kidney in response to genistein or daidzein were not signif-
icant when compared to vehicle controls (data not shown).
Overall our data demonstrates a lung and heart metastases
promoting role for daidzein in ER (-) cancers.
In vehicle controls, 75% of mice presented with bone
metastases with an average of *6 metastatic foci/femur
with metastases. Only 12.5% of the genistein-treated and
37.5% of daidzein-treated mice presented with bone
metastases (Fig. 2e). This dramatic decrease in bone
metastases in genistein-treated mice was statistically sig-
niﬁcant (P\0.05), while the bone metastatic response to
daidzein was not statistically signiﬁcant when compared
to vehicle controls (Fig. 2c). For liver metastases, all of
the vehicle-treated mice demonstrated liver metastases at
an average of 29 metastatic foci/liver. From the genistein
treatment, 50% mice presented with liver metastases at an
average of 3 metastatic foci/liver and 75% of daidzein-
treated mice demonstrated liver metastases with an
average of 12.5 metastatic foci/liver (Fig. 2e). Genistein
signiﬁcantly decreased the average integrated density of
liver metastases/mouse by 500% compared to vehicle
controls (P\0.05). The observed decrease in liver met-
astatic efﬁciency in response to daidzein was not statis-
tically signiﬁcant (Fig. 2d). Therefore, dietary treatment
with genistein speciﬁcally decreased bone and liver
metastases.
Study 2: effects of soy isoﬂavones on metastasis
The effect of combined soy (genistein:daidzein:glycitein,
5:4:1) treatment on established mammary fat pad tumors
was tested in two independent experiments that showed
similar results. Since the nude mouse litters as well as the
passage and amount of cells used were different for Study 1
(comparison of vehicle, genistein, or daidzein diets) and
Study 2 (comparison of vehicle with soy isoﬂavone com-
bination, genistein, daidzein, and glycitein), the results
were analyzed separately and compared with the vehicle
treatments for that study.
As shown in Fig. 3, both vehicle and soy-treated groups
demonstratedlungmetastasesinamajorityofthemice.Lungs
from soy isoﬂavone-treated mice presented with increased
number and area of metastatic lesions with an average of
154 metastaticfoci/lungcomparedto31 metastatic foci/lung
fromvehicle-treatedmice.Theaveragenumbersofmetastatic
foci/lung (35 and 31) are comparable for the vehicle-treated
mice from both Study 1 and Study 2. The increased number
andareaoflungmetastasesinthesoy-treatedmiceresultedin
a *36-fold statistically signiﬁcant increase in integrated
density of ﬂuorescence (P\0.05, Fig. 3a, f).
Vehicle treated mice did not demonstrate any heart
metastases while treatment with soy isoﬂavones resulted in
50% of the mice showing heart metastases with an average
of 6.5 metastatic foci/heart and an average integrated
density of 1.9 (Fig. 3b). In vehicle controls, 20% of mice
presented with bone metastases with an average of *1
metastatic lesion/femur with metastases. Following soy
isoﬂavone treatment, 50% of mice presented with bone
metastases with an average of 44 metastatic foci/femur and
a 14-fold signiﬁcant increase in integrated density
(P\0.05, Fig. 3c). For liver metastases, 50% of the
vehicle-treated mice and 87.5% of soy-treated mice dem-
onstrated ﬂuorescent metastatic foci where the vehicle
treated mice demonstrated an average of 10 metastatic
foci/liver while the soy treated mice presented with 169
metastatic foci/liver with a ﬁvefold statistically signiﬁcant
increase in integrated density compared to vehicle
(P\0.05, Fig. 3d). Similarly, kidney metastases were also
signiﬁcantly increased by the soy treatment where only
20% of vehicle treated mice demonstrated 2 metastatic
foci/kidney while soy isoﬂavone treatment resulted in
37.5% of mice with kidney metastases demonstrating
20 metastatic foci/kidney and a *25-fold increase in
average integrated density (P\0.05, Fig. 3e). These
results indicate that although combined dietary soy iso-
ﬂavones do not affect primary tumor size, consumption of
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123Fig. 3 Effect of soy isoﬂavones on metastasis. a Images of repre-
sentative lungs and ﬂuorescence image analysis of lungs from mice
following vehicle or soy isoﬂavones treatment. The average area of
ﬂuorescent metastatic foci was calculated from excised lungs after
vehicle or soy isoﬂavone (genistein:daidzein:glycitein, 5:4:1 ratio)
treatment (images of representative lungs are shown). b Fluorescence
image analysis of hearts from mice following vehicle or soy
isoﬂavone treatment. c Fluorescence image analysis of bones from
mice following vehicle or soy isoﬂavone treatment. d Fluorescence
image analysis of livers from mice following vehicle or soy
isoﬂavone treatment. e Fluorescence image analysis of kidneys from
mice following vehicle or soy isoﬂavone treatment. Integrated density
of ﬂuorescent metastatic foci/mouse ± SEM for n = 8/treatment is
shown. Asterisk denotes statistical signiﬁcance (P\0.05) compared
to vehicle controls. f The percentage of mice with metastases for each
organ (bone, heart, kidney, liver, lung) after soy isoﬂavone treatment,
as detected from ﬂuorescence images (n = 8)
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123soy can signiﬁcantly increase metastasis to all distant
organs examined.
Effect of soy isoﬂavones on expression of metastasis-
promoting molecules
Effect of soy isoﬂavones on gene expression
Since many of the members of the PI3 kinase/Akt pathway
have been implicated in cancer survival, invasion, and thus,
metastasis [49, 50], the differences in gene expression in
primary tumors following dietary treatments were deter-
mined using PI3-K real time PCR arrays. Gene expression
of tumors from vehicle, genistein, daidzein, or combined
soy treated mice were individually assessed using the
2
(-DCt) formula by comparing their relative gene expres-
sion to reference genes (Fig. 4). Table 1 shows genes with
a -1.3 C 1.3-fold change and statistical signiﬁcance
(P\0.05) compared to controls.
Study 1
Compared to vehicle, genistein signiﬁcantly dowregulated
10/84 genes (12%) and daidzein upregulated 9/84 (11%)
genes, consistent with decreased mammary tumor growth
by genistein and increase by daidzein. These numbers are
consistent with the predicted value under the null hypoth-
esis since *100 genes were studied, the expected number
with P-values\0.05 would be *5. Genistein downregu-
lated Ras/mitogen activated protein kinase (MAPK) path-
way: MAPK -1.3-fold, P = 0.06), GRB2, and RASA1 (Ras
GTPase activating protein) (P\0.05) and cell survival
(AKT1) genes, while daidzein signiﬁcantly increased Ras/
MAPK pathway and cell cycle progression regulators:
GRB2, MAPK, JUN, CCND1 (cyclin D1), CTNNB1 (beta
catenin), and IRS1 (insulin receptor substrate 1). Genistein
decreased PABPC1 (poly(A) binding protein) and daidzein
increased EIF4G1 (eukaryotic initiation factor F4G1)
expression implicating differential protein translational
regulation of mammary tumor growth by soy isoﬂavones.
Genistein also downregulated genes involved with invasion
and metastasis such as RHOA, RAC1, CDC42, and PAK1
(p21/Cdc42/Rac1-activated kinase 1).
Study 2
The combined soy isoﬂavones treatment did not show such
dramatic changes in expression of genes involved in the
PI3-K/Akt pathway, and only demonstrated a single gene
upregulated (EIF4E) and a single gene downregulated
(TIRAP) in a statistically signiﬁcant manner (Fig. 4). A
number of genes that were downregulated by genistein
Fig. 4 Effect of dietary soy isoﬂavones on PI3-K pathway gene
expression. Total RNA was extracted from mammary tumors excised
from mice that received vehicle, genistein, daidzein, or soy isoﬂavone
combination (genistein, daidzein, glycitein) diets. RT
2 PCR array
designed to proﬁle the expression of PI3-K pathway-speciﬁc genes
was used, according to manufacturer’s instructions (SA Biosciences).
Volcano plots show a genistein; b daidzein; c soy combination effects
on gene expression analyzed at -1.3 C 1.3 log2-fold change (dashed
line). Down-regulated genes are to the left of the vertical black line
while up-regulated genes are to the right. Statistically signiﬁcant
regulated genes are above the horizontal black line at P\0.05
(n = 3)
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123were also downregulated by the soy treatment as were
genes upregulated by daidzein (see Supplemental Infor-
mation Table 1). Interestingly, the majority of these
changes were not statistically signiﬁcant at a P value
\0.05. Therefore, combined soy isoﬂavone treatment may
neutralize the effects of the major soy isoﬂavones genistein
and daidzein in regulating the expression of PI3-K pathway
genes.
Effect of soy isoﬂavones on protein expression
The signiﬁcant downregulation of gene expression of Rho
GTPases RHO, RAC, and CDC42, and their downstream
effector PAK by genistein treatment was conﬁrmed by
western blotting of primary tumor extracts from vehicle,
genistein, or daidzein-treated mice. GFP expression was
detected to ensure equal protein levels and the source of
human breast cancer cells. Genistein treatment resulted in
*1.5–2-fold reduced gene and protein expression of Pak1,
Cdc42, Rac1, and RhoA (Fig. 5a). Daidzein treatment did
not show signiﬁcant differences in gene expression of Rho
GTPases and their downstream effector PAK1, but dem-
onstrated a ﬁvefold signiﬁcant increase in Rac1 protein
expression compared to vehicle controls (Fig. 5b). This
novel result indicates that the elevation of Rac levels by
daidzein is post-transcriptionally regulated while down-
regulation of Rac, Rho, Cdc42, and Pak1 expression by
genistein is transcriptionally regulated. Conﬁrming the
results of the PCR array, combined soy isoﬂavone treat-
ment did not signiﬁcantly change Rho, Rac, Cdc42, or Pak
levels in primary tumors (data not shown).
Since the PCR array data showed elevated EIF4G lev-
els, we determined whether daidzein treated primary
tumors demonstrated a parallel increase in eIF4G protein
levels. As shown in Fig. 6, compared to vehicle, genistein
treatment did not signiﬁcantly change eIF4G or eIF4E
levels but dietary daidzein signiﬁcantly increased eIF4G
levels by 3.5-fold and eIF4E levels by sevenfold in primary
mammary tumors (P\0.05) (Fig. 6a). The combined soy
treatment did not signiﬁcantly change eIF4G but demon-
strated a signiﬁcant 2.5-fold upregulation of eIF4E levels in
the tumors (Fig. 6b). Since, eIF4E is known to selectively
target the expression of mRNAs that regulate cancer cell
proliferation and survival [51, 52], the expression of sur-
vivin, a member of the inhibitors of apoptosis (IAP) family
[53], was monitored in tumors from mice following vehicle
or soy isoﬂavones. In these experiments, the integrated
density of bands positive for eIF4G, eIF4E, or survivin
were normalized with the density for actin or GFP and the
fold changes were found to be similar. As shown in Fig. 6a,
b, relative expression of actin for each mouse tumor
remained unchanged. Actin levels were used as a control
for these results because studies have shown that mRNAs
with long structured 50untranslated regions (UTR) such as
Table 1 Effect of soy isoﬂavones on expression of PI3-kinase pathway genes
Gene symbol—complete name Fold change, P value
Genistein Daidzein Soy combination
a
AKT1—v-akt murine thymoma viral oncogene homolog 1 -1.32, 0.02
CCND1—Cyclin D1 1.31, 0.05
CDC42—Cell division cycle 42 (GTP binding protein) -1.54, 0.04
CTNNB1—Catenin (cadherin-associated protein), beta 1 1.68, 0.03
EIF4E—Eukaryotic translation initiation factor 4E 1.82, 0.01
EIF4G1—Eukaryotic translation initiation factor 4 gamma 1 2.29, 0.03
GRB2—Growth factor receptor-bound protein 2 -1.64, 0.007 1.50, 0.04
GSK3B—Glycogen synthase kinase 3 beta 1.63, 0.02
IRAK1—Interleukin-1 receptor associated kinase 1.60, 0.006 2.71, 0.0001
IRS1—Insulin receptor substrate 1 2.05, 0.04
JUN—Jun oncogene 1.54, 0.04
MAPK1—Mitogen-activated protein kinase 1 1.31, 0.03
PABPC1—Poly(A) binding protein -1.65, 0.04
PAK1—p21 protein (Cdc42/Rac)-activated kinase 1 -2.01, 0.008
RAC1—Ras-related C3 botulinum toxin substrate 1 -1.73, 0.03
RASA1—RAS p21 protein activator (GTPase activating protein) -1.88, 0.02
RHOA—Ras homolog gene family, member A -1.78, 0.05
TIRAP—Toll-interleukin 1 receptor (TIR) domain containing adaptor protein -3.11, 0.008
Only genes that demonstrated -1.3[1.3-fold difference and P\0.05 from RT
2 PCR arrays are shown
a Soy combination (5:4:1, genistein:daidzein:glycitein)
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while genes with short 50UTRs such as actin are not sen-
sitive to eIF4 levels [51, 52]. Results show that genistein
signiﬁcantly inhibited survivin expression in mammary
tumors by 1.65-fold when compared to vehicle controls
while daidzein signiﬁcantly upregulated survivin protein
expression by 1.95-fold (P\0.05) (Fig. 6c). The com-
bined soy isoﬂavones treatment increased survivin
expression by 1.5-fold but this increase was not statistically
signiﬁcant. Therefore, daidzein may promote cancer
progression via increased translation of speciﬁc mRNAs
relevant for cancer cell survival such as survivin.
Discussion
An aggressive bone metastatic variant of the MDA-MB-
435 cancer cell line was used as a model system to
investigate the effect of soy isoﬂavones on mammary
cancer progression. To our knowledge, this is the ﬁrst time
that the effects of dietary soy isoﬂavones were assessed on
bone metastases from primary mammary tumors in a nude
mouse model. Investigation of the effect of dietary cancer
chemopreventives on bone metastasis is important because
most breast cancers in humans preferentially metastasize to
the bone [54]. Because the MDA-MB-435 cells were
inoculated at the mammary fat pad, this strategy enabled
the investigation of metastases to a number of distant
organs. Our results demonstrate an inhibitory role for
genistein and a promoting role for daidzein and combined
soy isoﬂavones in breast cancer progression. Genistein
(5,7-dihydroxy-3-(4-hydroxyphenyl) chromen-4-one or
Fig. 5 Effect of genistein and daidzein on gene and protein
expression of Rho GTPases and Pak1. Total lysates of mammary
tumors were western blotted with anti Pak1, RhoA, Rac, Cdc42, or
GFP antibodies. a Representative western blot for tumor extracts from
vehicle, genistein or daidzein treatments. b Fold changes in Rho
GTPase gene or protein expression for tumors from genistein- or
daidzein-treated mice compared to vehicle. log2-fold changes in gene
expression were calculated from PCR arrays. Fold changes in protein
expression were calculated from integrated density of positive bands
from western blots. Equal total protein content as well as conﬁrmation
of human cancer cells in the mouse tumor extracts was maintained by
expressing the integrated density of each band for Pak1, RhoA, Rac1,
or Cdc42 as a function of the integrated density of the GFP band from
the same tumor extract. Values show mean ± SEM (n = 6). An
asterisk indicates statistical signiﬁcance of P\0.05
Fig. 6 Effect of soy isoﬂavones on protein expression. Total lysates
of mammary tumors from mice treated with vehicle, genistein,
daidzein, or soy (genistein:daidzein:glycitein, 5:4:1 ratio) were
western blotted with anti-eIF4G, anti-eIF4E, or anti-survivin antibod-
ies. a Representative western blots for tumor extracts from vehicle,
genistein, or daidzein. b Representative western blots for tumor
extracts from vehicle, or combined soy treatments. c Fold changes in
eIF4G, eIF4E, and survivin protein expression for tumors from
genistein, daidzein, or soy treated mice compared to vehicle as
calculated from the integrated density of positive bands from western
blots and normalized with actin expression. Values show mean ±
SEM (n = 4). An asterisk indicates statistical signiﬁcance of P\0.05
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12340,5,7-Trihydroxyisoﬂavone) and daidzein (7-hydroxy-3-
(4-hydroxyphenyl) chromen-4-one or 40,7-Dihydroxyisof-
lavone) are structurally different only in the hydroxyl
group in position 5. Glycitein (40,7-dihydroxy-6-methox-
yisoﬂavone) has a methoxy group in position 6, and as in
the case of daidzein, glycitein does not have the hydroxyl
group in position 5. Nevertheless, as shown in the present
study, this slight structural difference could play a crucial
role in the estrogenic/antiestrogenic (or other biological)
activities of these compounds.
Isoﬂavones have short half-lives (*8 h), and nearly all
are excreted within 24 h after ingestion [55]. Results from
a recent report using rats show that genistein can be
detected in serum 5 min post-oral administration [56].
Because of rapid mouse metabolism, a 10 mg/kg BW
mouse dose can be considered equivalent to 1 mg/kg BW
in humans (an approximation of a high Asian soy diet). In
our studies, isoﬂavones were administered by gavage three
times a week at 10 mg/kg BW for individual isoﬂavones
and at 10 mg/kg BW genistein, 9 mg/kg BW daidzein, and
1 mg/kg BW glycitein for combined isoﬂavones. Thus, the
mice received a continuous isoﬂavone diet. The diet of
10 mg/kg-BW genistein in a *20–25 mg mouse works out
to be 0.2 mg genistein/mouse at *7 mM concentration.
Although we did not determine the levels of soy isoﬂav-
ones in tumor tissue, previous mouse studies have reported
isoﬂavone levels at 1.2 mg/g tissue daidzein and 6.5 mg/g
tissue for genistein following genistein or soy diets [17].
The plasma concentrations of mice receiving dietary gen-
istein similar to those used in the present study have been
reported to be in the range of the plasma concentrations
found in humans after soy consumption [33, 57].
We demonstrate an inhibitory role for genistein and a
promoting role for daidzein in tumor growth and metasta-
sis. Moreover, combined soy isoﬂavones (genistein,
daidzein, and glycitein) in the ratio found in soy foods did
not affect tumor growth at the mammary fat pad but
increased metastasis to all organs tested. These results were
obtained with high dietary concentrations and the effect of
soy isoﬂavones in our system at low concentrations remain
to be tested. Genistein is known to have a biphasic effect
on tumor growth and metastasis, where low concentrations
are stimulatory and high concentrations are inhibitory [21].
Similar to our results, an inhibitory role for genistein in
mammary tumor growth and metastatic progression has
been reported for both ER (?) and ER (-) breast cancers
[16, 58], while daidzein was shown to stimulate cell and
tumor growth of ER (?) MCF-7 non-metastatic breast
cancer cells in ovariectomized nude mice [59]. Moreover,
in the ER b positive MDA-MB-231 cell line, even though
genistein inhibited cell growth at all concentrations tested,
dietary genistein did not affect growth of subcutaneous
tumors from MDA-MB-231 cells in nude mice [60].
Herein, using the highly metastatic ER (-) MDA-MB-435
cell line to establish mammary fat pad tumors in nude
mice, we show that dietary daidzein increased tumor
growth and metastatic efﬁciency indicating that the tumor
promoting effect of daidzein is not ER dependent. Dietary
genistein and soy phytochemical concentrate have been
shown to reduce primary tumor growth and metastasis in
bladder and prostate cancer models [17, 33], while other
studies have shown that soy isoﬂavones, particularly gen-
istein, increased the growth of MCF-7 human breast cancer
cells and tumors in ovariectomized nude mice and meta-
static progression of prostate cancer [20, 21]. The results
shown herein using an ER (-) Her-2 (??) highly meta-
static cancer cell line may reﬂect the role of soy isoﬂavones
on mammary tumor growth and metastases from such
aggressive cancers.
Mice that received dietary genistein speciﬁcally dem-
onstrated reduced bone and liver metastases in a statisti-
cally signiﬁcant manner indicating a potential site-speciﬁc
inhibition of extravasation and (or) secondary tumor
establishment at these sites. Previous studies have shown
that genistein inhibits MMP secretion [13] and cell inva-
sion [26], which may lead to the observed reduction in
invasion to distant sites in genistein-treated mice. Unlike
previous studies that showed that genistein causes a
decrease in lung metastases from the MDA-MB-435 lung
metastatic variant and prostate and bladder cancer models
[16, 17, 33], our data did not show a signiﬁcant difference
in lung metastases in response to dietary genistein. This
difference in the genistein response maybe due to differ-
ences in the protocols, where; (1) we used a bone meta-
static variant of the parental MDA-MB-435 cell line, (2)
we did not initiate dietary treatments until mammary
tumors were established (*0.5 mm
2), and (3) we admin-
istered genistein at 10 mg/kg BW 39 a week by direct oral
gavage instead of incorporating into the mouse chow. The
preventive effects of genistein on metastasis that have also
been shown previously using the same (Her-2)?? MDA-
MB-435 model [16] may be due to the reported inhibitory
effects of genistein on Her-2 expression and phosphoryla-
tion, thus activation [61]. Future studies will assess the
effect of genistein on invasion/metastasis of mammary
tumors using a cell line such as MDA-MB-231 that does
not overexpress Her-2 or EGFR but exhibits some lung
metastasis in the nude mouse model.
We have previously shown that daidzein promoted cell
functions relevant for metastasis such as FAK activity,
focal adhesion assembly, extension of actin structures that
promote cell migration, and cell migration to a greater level
than genistein in breast cancer cell lines [62]. The present
study expands these observations to show that dietary
daidzein promotes lung, and heart metastases compared to
vehicle and genistein treatments. Moreover, dietary soy
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evaluated. The signiﬁcant increased incidence of lung and
heart metastases in daidzein and soy isoﬂavone diets
indicate higher incidence of cancer cell intravasation into
the blood stream since the heart and lungs are the ﬁrst
organs encountered by invasive cancer cells in blood ves-
sels. Since the increased metastases caused by the daidzein
treatment parallels the increased primary tumor growth in
response to dietary daidzein, elevated metastatic efﬁciency
of the daidzein-treated mice may reﬂect the higher numbers
of cells that left the primary mammary tumors and invaded
into the circulatory system. The genistein treated mice that
presented with smaller mammary tumors but did not sig-
niﬁcantly change lung, heart, or kidney metastases, indi-
cates that metastatic efﬁciency of genistein-treated mice is
not directly correlated with primary mammary tumor size.
This observation is also reﬂected in mice following com-
bined soy isoﬂavone treatment that did not show changes in
primary tumor size. This null effect on primary tumor
growth by dietary soy isoﬂavones may be due to a potential
negation of the observed disparate effects of genistein and
daidzein on primary tumor growth. However, soy isoﬂav-
one treatment increased metastases to all organs indicating
that this effect was not dependent on primary mammary
tumor size or organ site but a non-speciﬁc overall increase
in metastatic efﬁciency by the combined effect of geni-
stein, daidzein, and glycitein at a 5:4:1 ratio. These effects
were exempliﬁed in some cases by the clear presence of
cancer cells in the gastrointestinal tract of mice after
combined soy isoﬂavones diets (data not shown).
The differential effects of soy isoﬂavones on mammary
tumor progression, i.e. primary tumor growth and metas-
tasis prevention to bone and liver by genistein, increased
primary mammary tumor progression and metastasis to the
heart and lungs by daidzein, and promotion of metastasis to
all organs by combined genistein, daidzein, and glycitein
may be due to a number of reasons. (1) Potential concen-
tration-dependent effects of each compound at different
organ sites can exist due to unequal distribution of the
dietary isoﬂavones and their metabolites leading to site-
speciﬁc effects on the expression of metastasis promoters
and suppressors. For instance, a recent study reported that
following daidzein consumption, high levels of daidzein
and its metabolite equol were found in bone tissue of mice
[63]. Thus, levels of daidzein may reach bone tissue in
concentrations high enough to be inhibitory even though
the decreased trend in metastasis to the bone following
daidzein diets was not statistically signiﬁcant when com-
pared to vehicle controls. Studies using the MCF-7 ER (?)
breast cancer cell line have shown that physiological con-
centrations of genistein induced while pharmacological
concentrations of genistein reduced expression of genes
that regulate cell cycle progression [56]. Therefore, higher
concentrations of genistein at bone and liver may function
to speciﬁcally inhibit establishment of metastases at these
sites. (2) In addition, the soy isoﬂavones may have dif-
ferential effects on tumor cell intravasation and extrava-
sation at various organ sites. Currently we are conducting
site-speciﬁc molecular analysis of the molecular signatures
at distant organs following soy isoﬂavone diets and expect
to correlate the changes in signaling molecules with dietary
interventions.
The observed tumor and organ site-dependent differ-
ences in the effects of daidzein, genistein or combined soy
isoﬂavones may be due to differences in the signaling
molecules that are expressed by the tumor cells in response
to these compounds. Therefore, gene expression proﬁles
were performed on RNA extracted from excised primary
mammary tumors of mice following vehicle or dietary soy
isoﬂavone treatments. Since the major isoﬂavones found in
soy (genistein, daidzein and glycitein) have been shown to
regulate cancer cell survival [10, 34, 56], the present study
was conducted to determine the gene expression proﬁles of
PI3-K signaling pathway molecules from primary mam-
mary tumors of mice following dietary genistein, daidzein
or soy combination treatments. PI3-K-catalyzed phos-
phorylation of the conversion of membrane phophatidyl
inositol bis phosphate (PIP2) to phosphatidyl inositol 3,4,5-
phosphate (PIP3) results in the activation of a number of
signaling pathways including Akt/mammalian target of
rapamycin (mTOR), Ras/MAPK, and FAK/Rac/Cdc42
pathways that can lead to cancer cell survival, proliferation,
and invasion [49, 50].
Our PCR array data show increases in the expression of
a number of genes that regulate cell growth and cell cycle
progression and protein translation in response to daidzein
while genistein reduced the expression of genes implicated
in cell survival, proliferation, and invasion. Moreover,
animals that were on the soy combination diet showed an
increase in the expression of one gene that regulates protein
synthesis, and a decrease in the expression of one gene that
is involved in the innate immune system response. How-
ever, transcriptional regulation of genes may not indicate
post-transcriptional, translational, or post translational
control. A recent study reported that genistein increased
tumor levels of FAK, p38 MAPK, and heat shock protein
(HSP27) but that these proteins were not activated by
phosphorylation [33]. Therefore, the reported differences in
gene and protein expression may not indicate protein
activity and regulation of speciﬁc protein activities by soy
isoﬂavones will be the focus of future studies.
Our novel report that in mammary tumors, dietary
genistein signiﬁcantly decreased both gene and protein
expression of Rho GTPases (Rho, Rac, and Cdc42) and the
downstream effector of Rac and Cdc42, PAK1, are sig-
niﬁcant for understanding the mechanism by which
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known to promote cancer progression by regulation of
actin dynamics, cell-extracellular matrix interactions, cell
cycle progression, cell survival, and invasion [64, 65]. At
high concentrations, genistein acts as a tyrosine kinase
inhibitor and inhibits Rho-dependent focal adhesion
assembly and actin cytoskeleton reorganization [66]. The
present data indicates that dietary genistein may reduce
breast cancer progression via transcriptional regulation of
Rho GTPases and PAK.
The reduced PABCP levels by genistein may also
indicate a global decrease in mRNA translation that may
account for the reduced expression of all of the proteins
that were tested. Other microarray studies have shown that
high concentrations of genistein reduced expression of
genes that regulate cell cycle progression and increased
expression of pro-apoptotic genes [67]. The reduction of
GRB2 and MAPK expression by genistein in the mammary
tumors may also lead to a decrease in Ras/MAPK activity
as seen in previous studies [68]. A recent PCR array study
that used human prostate cancer cell lines to determine the
effect of genistein and daidzein reported that 40 lM gen-
istein or 110 lM daidzein was effective at inhibiting cell
cycle progression and upregulated cyclin dependent kinase
inhibitors and cyclin H and downregulated cyclin depen-
dent kinases [25]. Our study, that used genistein and
daidzein at physiologically relevant concentrations, report
that while dietary genistein decreased the expression of
GRB2 and MAPK, dietary daidzein signiﬁcantly increased
the expression of cell cycle regulators and signaling mol-
ecules that promote cell cycle progression (Cyclin D1, b
catenin, GRB2, MAPK, JUN). Therefore, this data indicates
that at dietary concentrations, genistein and daidzein can
exert differential effects on genes that regulate cancer cell
invasion, survival, and proliferation and thus, contribute to
tumor malignancy.
Daidzein treatment did not change gene expression of
Rho GTPases or PAK1 in mammary tumors. However,
daidzein signiﬁcantly increased protein expression of Rac,
a central regulator of actin cytoskeletal changes during
cancer cell invasion [69]. Eukaryotic translation initiation
factors eIF4G (gene and protein) and eIF4E (protein) were
also upregulated by daidzein. The eIF4F complex (eIF4G,
E, A, B), that scans the 50UTR and unwinds mRNA sec-
ondary structure to expose the start codon for translation
initiation, has been shown to speciﬁcally regulate the
expression of mRNAs with long, highly structured UTRs.
The eIF4F complex members have been shown to be
overexpressed in advanced cancer and to be essential for
translation of a subset of proteins that regulate cellular
bioenergetics, survival, and proliferation [70–72]. Our
results show that translational regulation may be a mech-
anism by which daidzein exerts differential effects on
cancer progression because a number of proteins were
elevated in the mammary tumors following daidzein
including survivin, an inhibitor of apoptosis implicated
with cancer malignancy that has been shown to be sensitive
to eIF4E levels [51, 52, 73]. Recent studies have associated
increased survivin expression with cancer malignancy [73].
As shown by a previous study, where reduced survivin
levels by combined genistein and tamoxifen was attributed
to apoptosis in breast cancer cells [30], our data show
reduced survivin levels in mammary tumors in response to
genistein diets. Since increased survivin levels are expected
to reduce caspase activity and thus, apoptosis, differential
expression of survivin in tumors following daidzein or
genistein diets may contribute to the disparate effects of
genistein and daidzein on tumor growth and metastasis.
Dietary daidzein also increased IRS1 levels in tumors
suggesting that insulin-like growth factor receptor (IGFR)
signaling may be involved with increased breast cancer
progression by daidzein. Statistically signiﬁcant IRAK1
upregulation by both genistein (P\0.006) and daidzein
(P\0.001) may indicate a soy isoﬂavone mediated acti-
vation of Nf-jB and MAPK signaling. However, since
IRAK1 needs to be ubiquitinated to be active, increased
IRAK1 expression may not necessarily result in enhanced
NF-jB activity [74]. Similarly, upregulation of GSK3B
gene expression by daidzein is not indicative of upregula-
tion of its activity, which is downregulated by Akt sig-
naling [75]. Future studies will determine whether
expression of these genes in response to dietary daidzein
results in enhanced protein expression and activity that
contribute to cancer malignancy.
Combined soy isoﬂavones that signiﬁcantly increased
metastasis did not affect Rho GTPase expression but sig-
niﬁcantly increased eIF4E levels. Therefore, this study
indicates that modulation of protein synthesis may be a
novel mechanism of regulation for cancer metastasis. Since
soy isoﬂavones did not change primary tumor size and a
number of genes that were regulated by genistein or
daidzein were up- or down-regulated by the combination
diet in a parallel but statistically non-signiﬁcant manner, it
is possible that the effects of genistein and daidzein were
neutralized in the primary tumors by the combined soy
isoﬂavones treatment. Our results suggest that the increase
in distant metastasis by combined soy isoﬂavones occurs
via activation of molecular mechanism(s) independent of
the PI3-K pathway. It is possible that the presence of
glycitein, albeit at a much smaller concentration, could have
contributed to a combinatorial effect on metastasis. A recent
study reported that glycitein may act similar to genistein by
increasing apoptosis via reduction of the Bcl-2/Bax ratio
[10]. Future experiments will delineate the speciﬁc effects
of glycitein as well as the molecular mechanisms that reg-
ulate cancer metastasis following dietary soy isoﬂavones.
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123This study indicates that consumption of soy products
may have differential and complex effects on breast cancer
progression and metastasis to different organs. Recent
studies have shown that while dietary soy isoﬂavones do
not affect breast cancer, they may increase the risk of
colorectal cancer among women and prostate cancer
among men [76]. Others have shown that soy food con-
sumption was signiﬁcantly associated with decreased risk
of death and recurrence for breast cancer [77]. Thus, this
investigation is of considerable interest in the debate about
whether soy isoﬂavones promote or prevent breast cancer,
particularly the perils of using soy in women diagnosed
with breast cancer or those at high risk. However, caution
must be exercised with interpretation of our results, since
this study represents the effect of a single concentration of
soy isoﬂavones that reﬂect a high soy diet conducted with
an ER negative cancer cell line in non-ovariectomized nude
mice.
Acknowledgements This study was supported by AICR IIG 03-31-
06 and NIH/NIGMS SC3GM084824 to SD and NIH/NCCR
G12RR003035 and NIH/NIGMS S06GM050695 to UCC. We thank
Alexander Schlachterman for assistance with animal protocols and
Kristin M. Wall for image analysis.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A,
Feuer EJ, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J
Clin 5:71–96
2. Messina M, Caskill-Stevens W, Lampe JW (2006) Addressing
the soy and breast cancer relationship: review, commentary, and
workshop proceedings. J Natl Cancer Inst 98:1275–1284
3. Murkies AL, Teede HJ, Davis SR (2000) What is the role of
phytoestrogens in treating menopausal symptoms? Med J Aust
173(Suppl):S97–S98
4. Lampe JW, Nishino Y, Ray RM, Wu C, Li W, Lin MG, Gao DL,
Hu Y, Shannon J, Stalsberg H, Porter PL, Frankenfeld CL, Wa-
hala K, Thomas DB (2007) Plasma isoﬂavones and ﬁbrocystic
breast conditions and breast cancer among women in Shanghai,
China. Cancer Epidemiol Biomarkers Prev 16:2579–2586
5. Kumar N, Allen K, Riccardi D, Kazi A, Heine J (2004) Isoﬂav-
ones in breast cancer chemoprevention: where do we go from
here? Front Biosci 9:2927–2934
6. Rice S, Whitehead SA (2006) Phytoestrogens and breast cancer—
promoters or protectors? Endocr Relat Cancer 13:995–1015
7. Vincent A, Fitzpatrick LA (2000) Soy isoﬂavones: are they useful
in menopause? Mayo Clin Proc 75:1174–1184
8. Murphy PA, Song T, Buseman G, Barua K, Beecher GR, Trainer
D, Holden J (1999) Isoﬂavones in retail and institutional soy
foods. J Agric Food Chem 47:2697–2704
9. Chrzan BG, Bradford PG (2007) Phytoestrogens activate estrogen
receptor beta1 and estrogenic responses in human breast and bone
cancer cell lines. Mol Nutr Food Res 51:171–177
10. Sakamoto T, Horiguchi H, Oguma E, Kayama F (2009) Effects of
diverse dietary phytoestrogens on cell growth, cell cycle and
apoptosis in estrogen-receptor-positive breast cancer cells. J Nutr
Biochem. doi:10.1016/j.jnutbio.2009.06.010
11. Shao ZM, Wu J, Shen ZZ, Barsky SH (1998) Genistein inhibits
both constitutive and EGF-stimulated invasion in ER-negative
human breast carcinoma cell lines. Anticancer Res 18:1435–1439
12. Shao ZM, Wu J, Shen ZZ, Barsky SH (1998) Genistein exerts
multiple suppressive effects on human breast carcinoma cells.
Cancer Res 58:4851–4857
13. Li Y, Bhuiyan M, Sarkar FH (1999) Induction of apoptosis and
inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. Int J
Oncol 15:525–533
14. Lamartiniere CA, Murrill WB, Manzolillo PA, Zhang JX, Barnes
S, Zhang X, Wei H, Brown NM (1998) Genistein alters the
ontogeny of mammary gland development and protects against
chemically-induced mammary cancer in rats. Proc Soc Exp Biol
Med 217:358–364
15. Whitsett TG Jr, Lamartiniere CA (2006) Genistein and resvera-
trol: mammary cancer chemoprevention and mechanisms of
action in the rat. Expert Rev Anticancer Ther 6:1699–1706
16. Vantyghem SA, Wilson SM, Postenka CO, Al-Katib W, Tuck
AB, Chambers AF (2005) Dietary genistein reduces metastasis in
a postsurgical orthotopic breast cancer model. Cancer Res
65:3396–3403
17. Singh AV, Franke AA, Blackburn GL, Zhou JR (2006) Soy
phytochemicals prevent orthotopic growth and metastasis of
bladder cancer in mice by alterations of cancer cell proliferation
and apoptosis and tumor angiogenesis. Cancer Res 66:1851–1858
18. Magee PJ, McGlynn H, Rowland IR (2004) Differential effects of
isoﬂavones and lignans on invasiveness of MDA-MB-231 breast
cancer cells in vitro. Cancer Lett 20:835–841
19. Farina HG, Pomies M, Alonso DF, Gomez DE (2006) Antitumor
and antiangiogenic activity of soy isoﬂavone genistein in mouse
models of melanoma and breast cancer. Oncol Rep 16:885–891
20. Allred CD, Allred KF, Ju YH, Virant SM, Helferich WG (2001)
Soy diets containing varying amounts of genistein stimulate
growth of estrogen-dependent (MCF-7) tumors in a dose-depen-
dent manner. Cancer Res 61:5045–5050
21. El Touny LH, Banerjee PP (2009) Identiﬁcation of a biphasic role
for genistein in the regulation of prostate cancer growth and
metastasis. Cancer Res 69:3695–3703
22. Jeng YJ, Watson CS (2009) Proliferative and anti-proliferative
effects of dietary levels of phytoestrogens in rat pituitary GH3/
B6/F10 cells—the involvement of rapidly activated kinases and
caspases. BMC Cancer 9:334
23. Shon YH, Park SD, Nam KS (2006) Effective chemopreventive
activity of genistein against human breast cancer cells. J Biochem
Mol Biol 39:448–451
24. Kousidou OC, Tzanakakis GN, Karamanos NK (2006) Effects of
the natural isoﬂavonoid genistein on growth, signaling pathways
and gene expression of matrix macromolecules by breast cancer
cells. Mini Rev Med Chem 6:331–337
25. Rabiau N, Kossai M, Braud M, Chalabi N, Satih S, Bignon YJ,
Bernard-Gallon DJ (2010) Genistein and daidzein act on a panel
of genes implicated in cell cycle and angiogenesis by Polymerase
Chain Reaction arrays in human prostate cancer cell lines. Cancer
Epidemiol 34:200–206
26. Huang X, Chen S, Xu L, Liu Y, Deb DK, Platanias LC, Bergan
RC (2005) Genistein inhibits p38 map kinase activation, matrix
metalloproteinase type 2, and cell invasion in human prostate
epithelial cells. Cancer Res 65:3470–3478
478 Clin Exp Metastasis (2010) 27:465–480
12327. Brownson DM, Azios NG, Fuqua BK, Dharmawardhane SF,
Mabry TJ (2002) Flavonoid effects relevant to cancer. J Nutr
132:3482S–3489S
28. Guo Y, Wang S, Hoot DR, Clinton SK (2007) Suppression of
VEGF-mediated autocrine and paracrine interactions between
prostate cancer cells and vascular endothelial cells by soy iso-
ﬂavones. J Nutr Biochem 18:408–417
29. Vanden BW, Dijsselbloem N, Vermeulen L, Ndlovu N, Boone E,
Haegeman G (2006) Attenuation of mitogen- and stress-activated
protein kinase-1-driven nuclear factor-kappaB gene expression
by soy isoﬂavones does not require estrogenic activity. Cancer
Res 66:4852–4862
30. Mai Z, Blackburn GL, Zhou JR (2007) Genistein sensitizes
inhibitory effect of tamoxifen on the growth of estrogen receptor-
positive and HER2-overexpressing human breast cancer cells.
Mol Carcinog 46:534–542
31. Fang MZ, Chen D, Sun Y, Jin Z, Christman JK, Yang CS (2005)
Reversal of hypermethylation and reactivation of p16INK4a,
RARbeta, and MGMT genes by genistein and other isoﬂavones
from soy. Clin Cancer Res 11:7033–7041
32. Su Y, Simmen FA, Xiao R, Simmen RC (2007) Expression
proﬁling of rat mammary epithelial cells reveals candidate sig-
naling pathways in dietary protection from mammary tumors.
Physiol Genomics 30:8–16
33. Lakshman M, Xu L, Ananthanarayanan V, Cooper J, Takimoto
CH, Helenowski I, Pelling JC, Bergan RC (2008) Dietary geni-
stein inhibits metastasis of human prostate cancer in mice. Cancer
Res 68:2024–2032
34. Jin S, Zhang QY, Kang XM, Wang JX, Zhao WH (2010)
Daidzein induces MCF-7 breast cancer cell apoptosis via the
mitochondrial pathway. Ann Oncol 21:263–268
35. Chambers AF (2009) Inﬂuence of diet on metastasis and tumor
dormancy. Clin Exp Metastasis 26:61–66
36. Lacroix M (2009) MDA-MB-435 cells are from melanoma, not
from breast cancer. Cancer Chemother Pharmacol 63:567
37. Chambers AF (2009) MDA-MB-435 and M14 cell lines: identical
but not M14 melanoma? Cancer Res 69:5292–5293
38. Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, Yu
D (2004) Lineage inﬁdelity of MDA-MB-435 cells: expression of
melanocyte proteins in a breast cancer cell line. Cancer Res
64:3479–3485
39. Phadke PA, Mercer RR, Harms JF, Jia Y, Frost AR, Jewell JL,
Bussard KM, Nelson S, Moore C, Kappes JC, Gay CV, Mastro
AM, Welch DR (2006) Kinetics of metastatic breast cancer cell
trafﬁcking in bone. Clin Cancer Res 12:1431–1440
40. Price JE, Zhang RD (1990) Studies of human breast cancer
metastasis using nude mice. Cancer Metastasis Rev 8:285–297
41. Harms JF, Welch DR (2003) MDA-MB-435 human breast
carcinoma metastasis to bone. Clin Exp Metastasis 20:327–
334
42. Schlachterman A, Valle F, Wall KM, Azios NG, Castillo L,
Morell L, Washington AV, Cubano LA, Dharmawardhane SF
(2008) Combined resveratrol, quercetin, and catechin treatment
reduces breast tumor growth in a nude mouse model. Transl
Oncol 1:19–27
43. Castillo-Pichardo L, Martinez-Montemayor MM, Martinez JE,
Wall KM, Cubano LA, Dharmawardhane S (2009) Inhibition of
mammary tumor growth and metastases to bone and liver by
dietary grape polyphenols. Clin Exp Metastasis 26:505–516
44. Carlson AL, Hoffmeyer MR, Wall KM, Baugher PJ, Richards-
Kortum R, Dharmawardhane SF (2006) In situ analysis of breast
cancer progression in murine models using a macroscopic ﬂuo-
rescence imaging system. Lasers Surg Med 38:928–938
45. Wu A, Yu MC, Tseng CC, Pike MC (2008) Epidemiology of soy
exposures and breast cancer risk. Br J Cancer 98:9–14
46. Li D, Yee JA, McGuire MH, Murphy PA, Yan L (1999) Soybean
isoﬂavones reduce experimental metastasis in mice. J Nutr
129:1075–1078
47. Iishi H, Tatsuta M, Baba M, Yano H, Sakai N, Akedo H (2000)
Genistein attenuates peritoneal metastasis of azoxymethane-
induced intestinal adenocarcinomas in Wistar rats. Int J Cancer
86:416–420
48. Gallo D, Ferlini C, Fabrizi M, Prislei S, Scambia G (2006) Lack
of stimulatory activity of a phytoestrogen-containing soy extract
on the growth of breast cancer tumors in mice. Carcinogenesis
27:1404–1409
49. Stephens L, Williams R, Hawkins P (2005) Phosphoinositide 3-
kinases as drug targets in cancer. Curr Opin Pharmacol 5:357–
365
50. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigat-
ing downstream. Cell 129:1261–1274
51. Graff JR, Konicek BW, Carter JH, Marcusson EG (2008) Tar-
geting the eukaryotic translation initiation factor 4E for cancer
therapy. Cancer Res 68:631–634
52. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D,
Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, Chen Y,
Zhang H, Sissons S, Cox K, McNulty AM, Parsons SH, Wang T,
Sams L, Geeganage S, Douglass LE, Neubauer BL, Dean NM,
Blanchard K, Shou J, Stancato LF, Carter JH, Marcusson EG
(2007) Therapeutic suppression of translation initiation factor
eIF4E expression reduces tumor growth without toxicity. J Clin
Invest 117:2638–2648
53. Nachmias B, Ashhab Y, Ben-Yehuda D (2004) The inhibitor of
apoptosis protein family (IAPs): an emerging therapeutic target in
cancer. Semin Cancer Biol 14:231–243
54. Bussard KM, Gay CV, Mastro AM (2008) The bone microen-
vironment in metastasis; what is special about bone? Cancer
Metastasis Rev 27:41–55
55. Rowland I, Faughnan M, Hoey L, Wahala K, Williamson G,
Cassidy A (2003) Bioavailability of phyto-oestrogens. Br J Nutr
89 Suppl 1:S45–S58
56. Zhou S, Hu Y, Zhang B, Teng Z, Gan H, Yang Z, Wang Q, Huan
M, Mei Q (2008) Dose-dependent absorption, metabolism, and
excretion of genistein in rats. J Agric Food Chem 56:8354–8359
57. Franke AA, Ashburn LA, Kakazu K, Suzuki S, Wilkens LR,
Halm BM (2009) Apparent bioavailability of isoﬂavones after
intake of liquid and solid soya foods. Br J Nutr 102:1203–1210
58. Mai Z, Blackburn GL, Zhou JR (2007) Soy phytochemicals
synergistically enhance the preventive effect of tamoxifen on the
growth of estrogen-dependent human breast carcinoma in mice.
Carcinogenesis 28:1217–1223
59. Ju YH, Fultz J, Allred KF, Doerge DR, Helferich WG (2006)
Effects of dietary daidzein and its metabolite, equol, at physio-
logical concentrations on the growth of estrogen-dependent
human breast cancer (MCF-7) tumors implanted in ovariecto-
mized athymic mice. Carcinogenesis 27:856–863
60. Santell RC, Kieu N, Helferich WG (2000) Genistein inhibits
growth of estrogen-independent human breast cancer cells in
culture but not in athymic mice. J Nutr 130:1665–1669
61. Sakla MS, Shenouda NS, Ansell PJ, Macdonald RS, Lubahn DB
(2007) Genistein affects HER2 protein concentration, activation,
and promoter regulation in BT-474 human breast cancer cells.
Endocrine 32:69–78
62. Azios NG, Dharmawardhane S (2005) Role of phytoestrogens in
modulating focal adhesions and focal adhesion kinase (FAK)
activity in breast cancer cells. In: Li J, Li SA, Llombart-Bosch A
(eds) Hormonal carcinogenesis. Springer-Verlag, NY, pp 300–
307
63. Fonseca D, Ward WE (2006) Detection of isoﬂavones in mouse
tibia after feeding daidzein. J Med Food 9:436–439
Clin Exp Metastasis (2010) 27:465–480 479
12364. Vega FM, Ridley AJ (2008) Rho GTPases in cancer cell biology.
FEBS Lett 582:2093–2101
65. Vadlamudi RK, Kumar R (2004) p21-activated kinase 1: an
emerging therapeutic target. Cancer Treat Res 119:77–88
66. Ridley AJ, Hall A (1994) Signal transduction pathways regulating
Rho-mediated stress ﬁbre formation: requirement for a tyrosine
kinase. EMBO J 13:2600–2610
67. Lavigne JA, Takahashi Y, Chandramouli GV, Liu H, Perkins SN,
Hursting SD, Wang TT (2007) Concentration-dependent effects of
genistein on global gene expression in MCF-7 breast cancer cells:
an oligo microarray study. Breast Cancer Res Treat 110:85–98
68. Clark JW, Santos-Moore A, Stevenson LE, Frackelton AR Jr
(1996) Effects of tyrosine kinase inhibitors on the proliferation of
human breast cancer cell lines and proteins important in the ras
signaling pathway. Int J Cancer 65:186–191
69. Bosco EE, Mulloy JC, Zheng Y (2009) Rac1 GTPase: a ‘‘Rac’’ of
all trades. Cell Mol Life Sci 66:370–374
70. Silvera D, Arju R, Darvishian F, Levine PH, Zolfaghari L,
Goldberg J, Hochman T, Formenti SC, Schneider RJ (2009)
Essential role for eIF4GI overexpression in the pathogenesis of
inﬂammatory breast cancer. Nat Cell Biol 11:903–908
71. Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T,
Yee H, Cangiarella J, Arju R, Formenti SC, Schneider RJ (2007)
A hypoxia-controlled cap-dependent to cap-independent transla-
tion switch in breast cancer. Mol Cell 28:501–512
72. Ramirez-Valle F, Braunstein S, Zavadil J, Formenti SC,
Schneider RJ (2008) eIF4GI links nutrient sensing by mTOR to
cell proliferation and inhibition of autophagy. J Cell Biol
181:293–307
73. Krepela E, DankovaP,Moravcikova E,Krepelova A,ProchazkaJ,
Cermak J, Schutzner J, Zatloukal P, Benkova K (2009) Increased
expressionofinhibitorofapoptosisproteins,survivinandXIAP,in
non-small cell lung carcinoma. Int J Oncol 35:1449–1462
74. Conze DB, Wu CJ, Thomas JA, Landstrom A, Ashwell JD (2008)
Lys63-linked polyubiquitination of IRAK-1 is required for
interleukin-1 receptor- and toll-like receptor-mediated NF-kap-
paB activation. Mol Cell Biol 28:3538–3547
75. Lizcano JM, Alessi DR (2002) The insulin signalling pathway.
Curr Biol 12:R236–R238
76. Ward HA, Kuhnle GG, Mulligan AA, Lentjes MA, Luben RN,
Khaw KT (2010) Breast, colorectal, and prostate cancer risk in
the European Prospective Investigation into Cancer and Nutri-
tion-Norfolk in relation to phytoestrogen intake derived from an
improved database. Am J Clin Nutr 91:440–448
77. Shu XO, Zheng Y, Cai H, Gu K, Chen Z, Zheng W, Lu W (2009)
Soy food intake and breast cancer survival. JAMA 302:2437–2443
480 Clin Exp Metastasis (2010) 27:465–480
123